Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient tourism getting out of control?

This article was originally published in Clinica

Executive Summary

There are concerns that "patient tourism" is becoming unmanageable in Europe. There has been a marked increase in the trend of patients travelling within the EU to another country for medical care. This has happened since the European Court of Justice ruled that European statutory health insurance funds are obliged to fund treatments abroad, if they are not able to offer a timely and qualitatively similar treatment in the patient's home country (see Clinica No 967, p 6). The necessary administrative procedures for managing patient costs across borders are not sufficiently well developed to cope, however. This practice risks destabilising many countries' efforts to control healthcare expenses, a meeting of representatives from 44 member state social affairs ministries concluded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel